Vir Biotechnology, Inc.

Historical 13F Holders

Symbol
VIR
CUSIP
92764N102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92764N102 since 12/18/2024, newest first.

Filer % of Class Filed
State Street Corp 13G 5.9% 8/7/2026
Event 6/30/2026
Vanguard Portfolio Management LLC 13G/A Amendment 1 6.9% 7/31/2026
Event 6/30/2026
SB Investment Advisers (UK) Ltd 13G/A Amendment 4
6.5% 5/15/2026
Event 3/31/2026
Vanguard Portfolio Management LLC 13G 5.8% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 3 0% 3/27/2026
Event 3/13/2026
ARCH Venture Fund IX, L.P. 13D/A Amendment 7
8.5% 3/3/2026
Event 2/27/2026
SB Investment Advisers (UK) Ltd 13G/A Amendment 3
9.4% 2/17/2026
Event 12/31/2025
BlackRock, Inc. 13G/A Amendment 3 10.8% 4/28/2025
Event 3/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 6 9.24 k $103 k
2026 Q2 251 148 M $1.63 B
2026 Q1 270 140 M $1.26 B
2025 Q4 232 116 M $698 M
2025 Q3 228 107 M $614 M
2025 Q2 231 112 M $562 M
2025 Q1 248 93.3 M $605 M
2024 Q4 224 88.8 M $652 M
2024 Q3 210 88.7 M $664 M
2024 Q2 227 91.4 M $813 M
2024 Q1 227 94.5 M $958 M
2023 Q4 219 91.1 M $917 M
2023 Q3 224 88.6 M $830 M
2023 Q2 246 90.8 M $2.23 B
2023 Q1 249 88.9 M $2.06 B
2022 Q4 238 91.6 M $2.32 B
2022 Q3 235 87.0 M $1.68 B
2022 Q2 223 86.2 M $2.20 B
2022 Q1 220 81.2 M $2.09 B
2021 Q4 234 78.3 M $3.26 B
2021 Q3 193 74.5 M $3.24 B
2021 Q2 180 76.9 M $3.64 B
2021 Q1 177 75.7 M $3.87 B
2020 Q4 164 79.0 M $2.12 B
2020 Q3 131 70.1 M $2.41 B
2020 Q2 123 53.5 M $2.19 B
2020 Q1 66 37.9 M $1.30 B
2019 Q4 40 36.6 M $460 M